Paolo Tarantino: The highly awaited Breast Cancer trials with positive results
Paolo Tarantino, PhD in clinical research at the University of Milan, shared a post on X:
“Update:
- 5 of the highly awaited BC trials with positive results.
- one negative trial (but with positive OS).
- Results from the remaining trials expected in 2025.
- Breast oncology keeps moving extremely fast.”
“With ESMO23 and SABCS23 approaching, we may soon see the results from several potentially practice-changing trials in breast oncology.
Here’s a personal, non-exhaustive selection of highly awaited phase 3 trials that may shape practice within the next year.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023